References
- 1. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, et al. on behalf of the 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014. 13:917-30 DOI: 10.1016/j.autrev.2014.05.00110.1016/j.autrev.2014.05.001
- 2. An GD, Lim HH, Han JY. Laboratory Diagnosis of Antiphospholipid Syndrome. Clin Exp Thromb Hemost. 2017.3(1):2-7.
- 3. Uthman I, Khamashta M. Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum.2006. 1: 360–367 DOI: 10.1016/j.semarthrit.2006.01.00110.1016/j.semarthrit.2006.01.001
- 4. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002. 346(10):752–63. DOI: 10.1056/NEJMra002974
- 5. Caraiola S, Jurcuț C, Dima A, Băicuș C, Băicuș A. Antiphosphatidylethanolamine Antibodies and Deep Vein Thrombosis in Lupus Patients with Antiphospholipid Syndrome. Rev Romana Med Lab. 2018;26(2):243-50 DOI: 10.2478/rrlm-2018-000910.2478/rrlm-2018-0009
- 6. Gavriş C, Anghel M, Rădoi M, Gheorghiţă E, Duca L, Pamfil G, et al. Risk of recurrent thrombosis related to antiphospholipid antibodies, soluble CD40L and P selectin serum levels in patients with antiphospholipid syndrome secondary to systemic lupus eritematosus. Rev Romana Med Lab. 2010;18(3):23-30
- 7. Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res. 2015. 135(Suppl 1):S8-S11 DOI: 10.1016/S0049-3848(15)50432-510.1016/S0049-3848(15)50432-5
- 8. Passamonti F, Caramazza D, Mora B, Casalone R, Maffioli M. It is time to change thrombosis risk assessment for PV and ET? Best Pract Res Clin Haematol. 2014; 27(2):121-127 DOI: 10.1016/j.beha.2014.07.005
- 9. Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. BLOOD. 2017, 129(25):3285-3293.
- 10. Ahmed TS, Tewari P, Kaur J, Rizvi S, Nafsi T. Recurrence of Pulmonary Embolism While on Rivaroxaban: Treatment Failure. Chest Journal. 2016. 149(4):A05-05